Business Wire

FourKites Hires Supply Chain Veteran in Europe, Underscoring Significant Growth in International Ocean Visibility

18.5.2022 11:00:00 EEST | Business Wire | Press release

Share

Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean), bringing a wealth of experience to this booming area of the company’s business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005080/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Philippe Salles has been appointed FourKites’ Vice President of Strategic Solutions (Ocean). (Photo: Business Wire)

“I’m delighted to be joining FourKites,” says Philippe, who brings experience from CMA CGM, INTTRA and maritime research and consultancy firm Drewry. “Visibility has been ocean shippers’ top priority for decades, and today’s real-time visibility platforms have completely changed the game. In addition to its market-leading machine learning-driven platform, FourKites understands that industry mindset and professionalism are as important as the technology itself. We need to provide shippers with a long-term strategic vision for their supply chain to make them resilient and collaborative.”

Philippe is an industry veteran with a detailed understanding of current supply chain issues. In his new role at FourKites, he will work closely with FourKites shippers and carriers to support them as they execute the change management needed to improve end-to-end supply chain visibility. Moreover, he will accelerate time to value for FourKites users by removing operational pain points and maximising the effectiveness of the systems they use.

“Philippe has a rare depth of experience, especially when it comes to evolving some of the traditional areas of ocean shipping with new technology,” says Mathew Elenjickal, FourKites Founder and CEO. “His network, the trust he's built up in the industry and his expertise in supply chain management will be invaluable to our customers as we continue to drive innovation in ocean visibility.”

FourKites sees unprecedented ocean momentum

Salles’ appointment is the latest leap forward in FourKites’ momentum in supply chain visibility for seagoing container traffic. FourKites now tracks 98% of global ocean container traffic across more than 270 lanes and 120 carriers, and covers every container port in North America and all major ports in Europe.

Over the last 12 months, the company has seen:

  • 79% growth in the number of customers using supply chain visibility for international shipments, with a 23% jump in Q1 2022 alone
  • 215% growth in the volume of seagoing freight that it tracks, with a 190% increase in ocean shipments in EMEA
  • 16% growth in the number of ports tracked in EMEA, now totalling coverage of 239 ports in the region and 804 ports globally

In the last quarter, FourKites signed a number of new ocean customers, including Cardinal Health, Arizona Tile, LyondellBasell, McCain Foods, Roehm, Rove Concepts and Yamaha Motors, among many others.

LyondellBasell, to take one example, is a top-10 global chemicals producer with operations around the world. The company has been a FourKites customer since 2018, when it began tracking shipments across all modes of transport in North America. Based on its success to date with the FourKites platform, the company extended its contract with FourKites in Q1 2022 to track multimodal shipments in Europe.

“Global shippers love FourKites’ Dynamic OceanSM platform because it addresses the full spectrum of shipping issues,” says Philippe. “And the company’s proprietary Dynamic ETA® technology provides estimated times of arrival that are 20% to 40% more accurate than carrier-generated figures. That’s important because timing errors can add significantly to costs.”

FourKites’ Dynamic Ocean addresses the full spectrum of ocean shipping issues through advanced document management and collaboration features; state-of-the-art real-time tracking capabilities, including highly accurate predictive ETAs; and comprehensive multimodal visibility from port to door, including the yard, so shippers can identify and manage the root causes of escalating fees.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
Director of European PR for FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye